TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7802313

Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.01 mg/kg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Nubain (0.3 mg/kg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Morphine (0.3 mg/kg)
Number of subjects: 33
Study: 2454140

Group type: EXPERIMENTAL
Intervention: Iloprost infusion (1.0 to 3.0 ng/kg/min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 12
Study: 12617436

Group type: EXPERIMENTAL
Intervention: Early intervention (Cohort 1) - GPs identified patients with DU and prescribed HPET according to defined criteria.
Number of subjects: 1422

Group type: COMPARATOR
Intervention: Delayed intervention (Cohort 2) - GPs prescribed HPET later.
Number of subjects: 1422
Study: 31220957

Group type: EXPERIMENTAL
Intervention: Intralipid 20% infusion on the day of embryo transfer and a second dose on the day of pregnancy test
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control group (no intralipid therapy)
Number of subjects: 142
Study: 29736496

Group type: EXPERIMENTAL
Intervention: Paneer
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cheese
Number of subjects: 60
Study: 26764317

Group type: EXPERIMENTAL
Intervention: Energy and protein supplementation (300 kcal/d, 15 g protein/d)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Energy and protein supplementation
Number of subjects: 24

Group type: COMPARATOR
Intervention: No supplement
Number of subjects: 24
Study: 24225233

Group type: EXPERIMENTAL
Intervention: Weekly Cetuximab (400 mg/m2 loading dose one week prior to radiotherapy followed by weekly 250 mg/m2)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Concurrent daily Cisplatin (6 mg/m2) and radiotherapy (66 Gy in 24 fractions) without Cetuximab
Number of subjects: 102
Study: 22730377

Group type: EXPERIMENTAL
Intervention: VT induced with four extrastimuli (ES)
Number of subjects: 432

Group type: COMPARATOR
Intervention: VT induced with less than or equal to two ES
Number of subjects: 432

Group type: COMPARATOR
Intervention: VT induced with three ES
Number of subjects: 432

Group type: COMPARATOR
Intervention: VT induced with four ES
Number of subjects: 432

Group type: COMPARATOR
Intervention: EP-negative patients
Number of subjects: 432
Study: 20634747

Group type: EXPERIMENTAL
Intervention: Active warm-up (WU)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: WU with dynamic stretching (ADS)
Number of subjects: 27

Group type: COMPARATOR
Intervention: WU with static stretching (SPS)
Number of subjects: 27
Study: 18375877

Group type: EXPERIMENTAL
Intervention: New multidisciplinary intervention (geriatric assessment and management by nurses at home)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 151
Study: 15789123

Group type: EXPERIMENTAL
Intervention: Short-term group (14 patients)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Long-term group (14 patients)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (21 patients)
Number of subjects: 28
Study: 11773508

Group type: EXPERIMENTAL
Intervention: 1000 mL/d of green tea
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 1000 mL/d of black tea
Number of subjects: 35

Group type: COMPARATOR
Intervention: Hot water containing caffeine
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 1250 mL/d of black tea
Number of subjects: 35

Group type: COMPARATOR
Intervention: Hot water
Number of subjects: 35
Study: 10192639

Group type: EXPERIMENTAL
Intervention: Tacrine hydrochloride (maximum dose administered for 30 weeks)
Number of subjects: 234
Study: 7776299

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 250 mg intramuscularly
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 2104075

Group type: EXPERIMENTAL
Intervention: Omeprazole 120 mg (40 mg t.d.s.)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Omeprazole 160 mg (loading dose of 80 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Omeprazole 80 mg
Number of subjects: 11
Study: 392623

Group type: EXPERIMENTAL
Intervention: 0.2 mg prostaglandin E2
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 0.4 mg prostaglandin E2
Number of subjects: 84

Group type: COMPARATOR
Intervention: inert material (control)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 0.2 mg prostaglandin E2, 0.4 mg prostaglandin E2, inert material (control)
Number of subjects: 84
Study: 31142219

Group type: EXPERIMENTAL
Intervention: Direct transfer to endovascular center (endovascular treatment stroke center)
Number of subjects: 1754

Group type: COMPARATOR
Intervention: Standard transfer to the closest local stroke center (local-SC)
Number of subjects: 1754

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1754
Study: 28865351

Group type: EXPERIMENTAL
Intervention: Exogenous testosterone (topical gel)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 26633251

Group type: EXPERIMENTAL
Intervention: $15 gift card
Number of subjects: 4427

Group type: EXPERIMENTAL
Intervention: Lottery for $250 gift card
Number of subjects: 4427

Group type: EXPERIMENTAL
Intervention: Person-centered incentive with choice of $15 gift card or lottery
Number of subjects: 4427

Group type: COMPARATOR
Intervention: Control group (standard reminder letter)
Number of subjects: 4427
Study: 23928280

Group type: EXPERIMENTAL
Intervention: Erector spinae (ES) muscle activity during standing knee flexion
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hamstring muscle activity during standing knee flexion
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lumbar motion during standing knee flexion
Number of subjects: 30
Study: 21284022

Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Training (PFMT)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Bladder Training (BT)
Number of subjects: 83
Study: 19189940

Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) training replacing 12 conventional training sessions over 4 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 23
Study: 16925952

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Immediate clamping
Number of subjects: 230
Study: 12698087

Group type: COMPARATOR
Intervention: Cyclosporine A (CsA) continued with sirolimus (SRL) 2 mg/day (group I)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) 2 mg/day with early withdrawal of CsA (group II)
Number of subjects: 40
Study: 10933120

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 7
Study: 8637441

Group type: EXPERIMENTAL
Intervention: Very-low-density lipoprotein (VLDL) from hemodialysis patients
Number of subjects: 20
Study: 1455006

Group type: EXPERIMENTAL
Intervention: EPO therapy
Number of subjects: 34

Group type: COMPARATOR
Intervention: NO-EPO therapy (Control)
Number of subjects: 34
Study: 3913378

Group type: EXPERIMENTAL
Intervention: Diclofenac (32.5 mg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Indomethacin (25 mg)
Number of subjects: 31
Study: 31246052

Group type: EXPERIMENTAL
Intervention: TranS‐C intervention
Number of subjects: 176

Group type: COMPARATOR
Intervention: Psychoeducation (control)
Number of subjects: 176
Study: 30248943

Group type: EXPERIMENTAL
Intervention: Online 12-week walking intervention (STRIDE)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (pedometer only)
Number of subjects: 91
Study: 26792221

Group type: EXPERIMENTAL
Intervention: Lay health supporters (LHSs) intervention with mobile phone messaging system
Number of subjects: 258

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Lay health supporters (LHSs) intervention
Number of subjects: 258
Study: 23922377

Group type: EXPERIMENTAL
Intervention: 100 U vaccine
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: 200 U vaccine
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: 400 U vaccine
Number of subjects: 480

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study: 22723853

Group type: EXPERIMENTAL
Intervention: Benfluorex (150 to 450 mg/day)
Number of subjects: 846

Group type: COMPARATOR
Intervention: Pioglitazone (30 to 45 mg/day)
Number of subjects: 846
Study: 20103455

Group type: EXPERIMENTAL
Intervention: Intramuscular phloroglucinol (4 mL)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo (normal saline, 4 mL)
Number of subjects: 116
Study: 17762547

Group type: EXPERIMENTAL
Intervention: Novel ion channel blockers targeting atrial-specific ion channels or a combination of ion channels.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New drugs inhibiting fibrosis, cellular hypertrophy, and improving cell-cell communication.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Focal pharmacological modulation targeting specific pathways.
Number of subjects: 0
Study: 16153519

Group type: EXPERIMENTAL
Intervention: Interatrial electromechanical delay in MS group
Number of subjects: 25

Group type: COMPARATOR
Intervention: Interatrial electromechanical delay in control group
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: P-wave dispersion (PWD) in MS group
Number of subjects: 25

Group type: COMPARATOR
Intervention: P-wave dispersion (PWD) in control group
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Correlation between interatrial electromechanical delay and PWD
Number of subjects: 25
Study: 12161530

Group type: EXPERIMENTAL
Intervention: Insulin stimulation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Regional glucose uptake rates
Number of subjects: 20
Study: 9612823

Group type: EXPERIMENTAL
Intervention: Normative education (NORM) intervention
Number of subjects: 2370

Group type: EXPERIMENTAL
Intervention: Social pressure resistance training
Number of subjects: 2370

Group type: COMPARATOR
Intervention: Information-only control group
Number of subjects: 2370
Study: 8004580

Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin treatment
Number of subjects: 277

Group type: COMPARATOR
Intervention: Control (no heparin treatment)
Number of subjects: 277
Study: 2509214

Group type: EXPERIMENTAL
Intervention: Misoprostol (400 micrograms)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rioprostil (300 micrograms)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Enprostil (70 micrograms)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nocloprost (200 micrograms)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 766905

Group type: EXPERIMENTAL
Intervention: BCG immunotherapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no BCG treatment)
Number of subjects: 40
Study: 31393868

Group type: EXPERIMENTAL
Intervention: 3BNC117 and 10-1074 at 10 mg/kg, one infusion
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 3BNC117 and 10-1074 at 3 mg/kg every 8 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 3BNC117 and 10-1074 at 10 mg/kg every 8 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo infusions
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 3BNC117 and 10-1074
Number of subjects: 24
Study: 28606587

Group type: EXPERIMENTAL
Intervention: Higher maternal 25OHD levels at early pregnancy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Obesity
Number of subjects: 0
Study: 27087432

Group type: EXPERIMENTAL
Intervention: Abstinent 24 h (n = 21)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Smoking as usual (n = 18)
Number of subjects: 39
Study: 25103176

Group type: EXPERIMENTAL
Intervention: NtRTI-sparing regimen (400 mg raltegravir twice daily plus 800 mg darunavir and 100 mg ritonavir once daily)
Number of subjects: 805

Group type: COMPARATOR
Intervention: Standard regimen (tenofovir-emtricitabine 245 mg and 200 mg fixed-dose combination once daily, plus 800 mg darunavir and 100 mg ritonavir once daily)
Number of subjects: 805

Group type: EXPERIMENTAL
Intervention: NtRTI-sparing regimen
Number of subjects: 805

Group type: COMPARATOR
Intervention: Standard regimen
Number of subjects: 805
Study: 22674570

Group type: EXPERIMENTAL
Intervention: R-CHOP plus epratuzumab
Number of subjects: 254

Group type: COMPARATOR
Intervention: Standard R-CHOP
Number of subjects: 254
Study: 19597081

Group type: EXPERIMENTAL
Intervention: creatine (n = 67)
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: minocycline (n = 66)
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: coenzyme Q10 (n = 71)
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: GPI‐1485 (n = 71)
Number of subjects: 413

Group type: COMPARATOR
Intervention: placebo (n = 138)
Number of subjects: 413
Study: 17615828

Group type: EXPERIMENTAL
Intervention: Active intervention PCG (children received a series of interventions including gift bags with a trainer cup, fluoride toothpaste (1450 ppm F), toothbrush, and parental advice on oral care)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison PCG (no specific interventions mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All children (participants and non-participants) in the active PCG
Number of subjects: 0

Group type: COMPARATOR
Intervention: All children (participants and non-participants) in the comparison PCG
Number of subjects: 0
Study: 14748760

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg daily)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Fluvastatin (40 mg daily)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (12 healthy subjects, no drug administration)
Number of subjects: 35
Study: 11718678

Group type: EXPERIMENTAL
Intervention: Mulberry therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Glibenclamide treatment
Number of subjects: 24
Study: 9752889

Group type: EXPERIMENTAL
Intervention: Moderate dietary sodium reduction (200 to 100 mmol/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Strict dietary sodium reduction (30 mmol/day)
Number of subjects: 12
Study: 8001210

Group type: EXPERIMENTAL
Intervention: Video-instructed ICU staff raters
Number of subjects: 16

Group type: COMPARATOR
Intervention: Expert ratings
Number of subjects: 16
Study: 2455740

Group type: COMPARATOR
Intervention: 5% human serum albumin (albumin)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (hetastarch)
Number of subjects: 12
Study: 1986730

Group type: EXPERIMENTAL
Intervention: Thiamine at 3 g/d
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 333252

Group type: EXPERIMENTAL
Intervention: Doxepin 75 mg daily for 14 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30831041

Group type: EXPERIMENTAL
Intervention: Pazopanib-induced proteinuria
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Pazopanib-induced hypothyroidism
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Pazopanib-induced cardiotoxicity grade 3-4
Number of subjects: 259
Study: 28272252

Group type: EXPERIMENTAL
Intervention: remifentanil 0.35 μg/kg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: esmolol 0.5 mg/kg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: esmolol 1 mg/kg
Number of subjects: 120

Group type: COMPARATOR
Intervention: normal saline
Number of subjects: 120
Study: 26259542

Group type: EXPERIMENTAL
Intervention: BCG vaccination at birth
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BCG vaccination at 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: BCG vaccination at birth vs 8 weeks
Number of subjects: 0
Study: 25010879

Group type: EXPERIMENTAL
Intervention: Full veneer (FV) restorations
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Overlap (OV) restorations
Number of subjects: 25

Group type: COMPARATOR
Intervention: All-ceramic veneers (both designs)
Number of subjects: 25
Study: 22463973

Group type: EXPERIMENTAL
Intervention: IV pantoprazole, antacid, and antispasmodic
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo, antacid, and antispasmodic (conventional group)
Number of subjects: 87
Study: 18365224

Group type: EXPERIMENTAL
Intervention: 1 x 6 mL hylan G-F 20
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 3 x 4 mL hylan G-F 20
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 3 x 2 mL hylan G-F 20
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 2 x 4 mL hylan G-F 20 (2 weeks apart)
Number of subjects: 100
Study: 17229535

Group type: EXPERIMENTAL
Intervention: Bifidobacter lactis supplemented preterm formula (2 x 10(7) cfu/g of dry milk)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (same formula without supplementation)
Number of subjects: 41
Study: 15152291

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11842907

Group type: EXPERIMENTAL
Intervention: Titanium posts and composite cores
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Zirconia posts and composite cores
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Zirconia posts with heat-pressed ceramic cores
Number of subjects: 64

Group type: COMPARATOR
Intervention: Cast posts and cores
Number of subjects: 64
Study: 9728556

Group type: EXPERIMENTAL
Intervention: Patients with multiple myeloma
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control patients with other cancers
Number of subjects: 27

Group type: COMPARATOR
Intervention: Blood donors
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Patients with progressive multiple myeloma
Number of subjects: 27
Study: 7752826

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ), 3.0‐3.4 mg/kg/day for 7 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (group 1, normals; group 4, asymptomatic children with MVP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Patients with load-induced cardiac dysfunction (group 2)
Number of subjects: 30
Study: 2544742

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) - 2,500 units 2 hours before surgery, then 5,000 units subcutaneously every morning for 9 days
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional low-dose heparin - 5,000 units every 8 hours
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional low-dose heparin
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) and Conventional low-dose heparin
Number of subjects: 90
Study: 31642731

Group type: EXPERIMENTAL
Intervention: ACT-541468 15 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ACT-541468 25 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ACT-541468 25 mg (repeated evening administration)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ACT-541468
Number of subjects: 24
Study: 30474592

Group type: EXPERIMENTAL
Intervention: Prognostic model for outcome 1 (presence of at least one of the following symptoms at 9 months: persistent pain, functional difficulty, lack of confidence)
Number of subjects: 1266

Group type: EXPERIMENTAL
Intervention: Prognostic model for outcome 2 (same symptoms as outcome 1 plus recurrence of injury)
Number of subjects: 1266

Group type: EXPERIMENTAL
Intervention: Updated models with additional variable (pain when bearing weight on the ankle) at 4 weeks post injury
Number of subjects: 1266

Group type: EXPERIMENTAL
Intervention: External validation of outcome 1 model
Number of subjects: 1266

Group type: EXPERIMENTAL
Intervention: External validation of outcome 2 model
Number of subjects: 1266
Study: 27563670

Group type: EXPERIMENTAL
Intervention: Hatha yoga training (8 weeks, 2 times/week, total of 16 sessions)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hatha yoga training
Number of subjects: 30
Study: 24363238

Group type: COMPARATOR
Intervention: Frovatriptan 2.5 mg alone (Frova)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Frovatriptan 2.5 mg + dexketoprofen 25 mg (FroDex25)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Frovatriptan 2.5 mg + dexketoprofen 37.5 mg (FroDex37.5)
Number of subjects: 314
Study: 22205619

Group type: EXPERIMENTAL
Intervention: Closed pleural drainage using a central venous catheter (CVC)
Number of subjects: 407

Group type: COMPARATOR
Intervention: Conventional chest tube
Number of subjects: 407
Study: 19915475

Group type: EXPERIMENTAL
Intervention: I-gel
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway (pLMA)
Number of subjects: 167

Group type: COMPARATOR
Intervention: classic laryngeal mask airway (cLMA)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: I-gel, pLMA, cLMA
Number of subjects: 167

Group type: COMPARATOR
Intervention: cLMA
Number of subjects: 167
Study: 18729683

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 61
Study: 16059992

Group type: EXPERIMENTAL
Intervention: Vitamin C (1000 mg/12 h infusion followed by 1200 mg/24 h orally) and Vitamin E (600 mg/24 h)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study: 12444833

Group type: EXPERIMENTAL
Intervention: Home visitation program
Number of subjects: 232

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 232
Study: 10411934

Group type: EXPERIMENTAL
Intervention: JE-2147
Number of subjects: 7

Group type: COMPARATOR
Intervention: KNI-272
Number of subjects: 7
Study: 8873488

Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention (comprehensive patient education, dietary and social service consultations, medication review, intensive postdischarge follow‐up)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Conventional care (control group)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention
Number of subjects: 156
Study: 1387607

Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg/day for one week
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High dose adrenaline infusion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ADP in vitro
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 10
Study: 6469443

Group type: EXPERIMENTAL
Intervention: 50 mg buflomedil
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 100 mg buflomedil
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 200 mg buflomedil
Number of subjects: 10

Group type: COMPARATOR
Intervention: 2000 mg piracetam
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10